PTCT: Broad PKU launch, strong pipeline, and global expansion drive growth and profitability
Management highlighted strong financials, broad PKU launch success, and a robust rare disease pipeline. International growth is expected to accelerate from 2026, with strategic pricing and reimbursement efforts underway. Recent acquisitions and disciplined OpEx support sustainable profitability.Bas…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.